212 related articles for article (PubMed ID: 37253131)
1. Autoantibodies Neutralizing Type III Interferons Are Uncommon in Patients with Severe Coronavirus Disease 2019 Pneumonia.
Vanker M; Särekannu K; Fekkar A; Jørgensen SE; Haljasmägi L; Kallaste A; Kisand K; Lember M; Peterson P; Menon M; Hussell T; Knight S; Moore-Stanley J; Bastard P; Zhang SY; Mogensen TH; Philippot Q; Zhang Q; Puel A; Casanova JL; Kisand K
J Interferon Cytokine Res; 2023 Sep; 43(9):379-393. PubMed ID: 37253131
[TBL] [Abstract][Full Text] [Related]
2. Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies.
Akbil B; Meyer T; Stubbemann P; Thibeault C; Staudacher O; Niemeyer D; Jansen J; Mühlemann B; Doehn J; Tabeling C; Nusshag C; Hirzel C; Sanchez DS; Nieters A; Lother A; Duerschmied D; Schallner N; Lieberum JN; August D; Rieg S; Falcone V; Hengel H; Kölsch U; Unterwalder N; Hübner RH; Jones TC; Suttorp N; Drosten C; Warnatz K; Spinetti T; Schefold JC; Dörner T; Sander LE; Corman VM; Merle U; ; Kurth F; von Bernuth H; Meisel C; Goffinet C
J Clin Immunol; 2022 Aug; 42(6):1111-1129. PubMed ID: 35511314
[TBL] [Abstract][Full Text] [Related]
3. Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α.
Mathian A; Breillat P; Dorgham K; Bastard P; Charre C; Lhote R; Quentric P; Moyon Q; Mariaggi AA; Mouries-Martin S; Mellot C; Anna F; Haroche J; Cohen-Aubart F; Sterlin D; Zahr N; Gervais A; Le Voyer T; Bizien L; Amiot Q; Pha M; Hié M; Chasset F; Yssel H; Miyara M; Charneau P; Ghillani-Dalbin P; Casanova JL; Rozenberg F; Amoura Z; Gorochov G
Ann Rheum Dis; 2022 Dec; 81(12):1695-1703. PubMed ID: 35973806
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain.
Troya J; Bastard P; Planas-Serra L; Ryan P; Ruiz M; de Carranza M; Torres J; Martínez A; Abel L; Casanova JL; Pujol A
J Clin Immunol; 2021 Jul; 41(5):914-922. PubMed ID: 33851338
[TBL] [Abstract][Full Text] [Related]
5. Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease.
Busnadiego I; Abela IA; Frey PM; Hofmaenner DA; Scheier TC; Schuepbach RA; Buehler PK; Brugger SD; Hale BG
PLoS Biol; 2022 Jul; 20(7):e3001709. PubMed ID: 35788562
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19.
Eto S; Nukui Y; Tsumura M; Nakagama Y; Kashimada K; Mizoguchi Y; Utsumi T; Taniguchi M; Sakura F; Noma K; Yoshida Y; Ohshimo S; Nagashima S; Okamoto K; Endo A; Imai K; Kanegane H; Ohnishi H; Hirata S; Sugiyama E; Shime N; Ito M; Ohge H; Kido Y; Bastard P; Casanova JL; Ohara O; Tanaka J; Morio T; Okada S
J Clin Immunol; 2022 Oct; 42(7):1360-1370. PubMed ID: 35764767
[TBL] [Abstract][Full Text] [Related]
7. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
8. Salivary autoantibodies to type I IFNs: Mirror plasma levels, predispose to severe COVID-19, and enhance feasibility for clinical screening.
Saheb Sharif-Askari N; Saheb Sharif-Askari F; Bayram OS; Hafezi S; Alsayed HAH; Kasim F; Mdkhana B; Selvakumar B; Alsafar HS; Halwani R
Heart Lung; 2024; 66():31-36. PubMed ID: 38547583
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia.
Philippot Q; Fekkar A; Gervais A; Le Voyer T; Boers LS; Conil C; Bizien L; de Brabander J; Duitman JW; Romano A; Rosain J; Blaize M; Migaud M; Jeljeli M; Hammadi B; Desmons A; Marchal A; ; ; Mayaux J; Zhang Q; Jouanguy E; Borie R; Crestani B; Luyt CE; Adle-Biassette H; Sene D; Megarbane B; Cobat A; Bastard P; Bos LDJ; Casanova JL; Puel A
J Clin Immunol; 2023 Aug; 43(6):1093-1103. PubMed ID: 37209324
[TBL] [Abstract][Full Text] [Related]
10. Autoantibodies Neutralizing Type I Interferons in 20% of COVID-19 Deaths in a French Hospital.
Chauvineau-Grenier A; Bastard P; Servajean A; Gervais A; Rosain J; Jouanguy E; Cobat A; Casanova JL; Rossi B
J Clin Immunol; 2022 Apr; 42(3):459-470. PubMed ID: 35083626
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies against type I interferons in COVID-19 infection: A systematic review and meta-analysis.
Wang X; Tang Q; Li H; Jiang H; Xu J; Bergquist R; Qin Z
Int J Infect Dis; 2023 May; 130():147-152. PubMed ID: 36907547
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19.
Abers MS; Rosen LB; Delmonte OM; Shaw E; Bastard P; Imberti L; Quaresima V; Biondi A; Bonfanti P; Castagnoli R; Casanova JL; Su HC; Notarangelo LD; Holland SM; Lionakis MS
Immunol Cell Biol; 2021 Oct; 99(9):917-921. PubMed ID: 34309902
[TBL] [Abstract][Full Text] [Related]
13. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
[TBL] [Abstract][Full Text] [Related]
14. Type I and type III interferons: From basic biology and genetics to clinical development for COVID-19 and beyond.
Andreakos E;
Semin Immunol; 2024 Mar; 72():101863. PubMed ID: 38271892
[TBL] [Abstract][Full Text] [Related]
15. Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia.
de Prost N; Bastard P; Arrestier R; Fourati S; Mahévas M; Burrel S; Dorgham K; Gorochov G; Tandjaoui-Lambiotte Y; Azzaoui I; Fernandes I; Combes A; Casanova JL; Mekontso-Dessap A; Luyt CE
J Clin Immunol; 2021 Apr; 41(3):536-544. PubMed ID: 33616813
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 mRNA vaccine, but not a viral vector-based vaccine, promotes neutralizing anti-type I interferon autoantibody production in a small group of healthy individuals.
Xu W; Wen X; Cong X; Jiang W
J Med Virol; 2023 Oct; 95(10):e29137. PubMed ID: 37792386
[TBL] [Abstract][Full Text] [Related]
17. Type I and III interferons are good markers to monitor COVID-19 pathophysiology.
Darif D; Ejghal R; Desterke C; Outlioua A; Hammi I; Lemrani M; Hilali F; Guessous F; Zaid Y; Akarid K
Cytokine; 2023 May; 165():156172. PubMed ID: 36924609
[TBL] [Abstract][Full Text] [Related]
18. No increased prevalence of autoantibodies neutralizing type I IFNs in idiopathic pulmonary fibrosis patients.
Philippot Q; Bastard P; Puel A; Casanova JL; Cobat A; Laouénan C; Tardivon C; Crestani B; Borie R
Respir Res; 2023 Mar; 24(1):87. PubMed ID: 36941652
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of SARS-CoV-2 by type I and type III interferons.
Felgenhauer U; Schoen A; Gad HH; Hartmann R; Schaubmar AR; Failing K; Drosten C; Weber F
J Biol Chem; 2020 Oct; 295(41):13958-13964. PubMed ID: 32587093
[TBL] [Abstract][Full Text] [Related]
20. Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona.
Solanich X; Rigo-Bonnin R; Gumucio VD; Bastard P; Rosain J; Philippot Q; Perez-Fernandez XL; Fuset-Cabanes MP; Gordillo-Benitez MÁ; Suarez-Cuartin G; Boza-Hernandez E; Riera-Mestre A; Parra-Martínez A; Colobran R; Antolí A; Navarro S; Rocamora-Blanch G; Framil M; Calatayud L; Corbella X; Casanova JL; Morandeira F; Sabater-Riera J
J Clin Immunol; 2021 Nov; 41(8):1733-1744. PubMed ID: 34570326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
